Millions of older Americans are about to gain cheaper access to blockbuster weight-loss drugs, and their doctors are bracing for impact. Starting July 1, a new Medicare program will offer drugs like Wegovy and Zepbound for $50 a month, potentially triggering one of the largest prescription surges in recent memory among an estimated 14 million overweight or obese beneficiaries, reports Axios. The price break stems from a deal between the Trump administration and drugmakers Eli Lilly and Novo Nordisk, which cut prices in return for broader access.
Clinicians warn that the system isn't ready, however. They expect already time-consuming "prior authorization" checks to spike, with some saying clinics would need to double or triple pharmacy staff to keep up—staffing they don't yet have. Medicare officials say they've streamlined the process and don't foresee major strain.
The program, which runs only through 2027, covers the drugs but not the nutrition and behavioral support often bundled in employer plans, raising concerns about rushed counseling and safety in older adults. In addition, the $50 copay won't count toward out-of-pocket caps and may still be too steep for some on fixed incomes.
Meanwhile, Eli Lilly and Novo Nordisk are targeting seniors in new ads, eyeing a lucrative expansion of the GLP-1 market, reports CNBC. The New York Times has a primer on what to know about the Medicare program kicking off next month, while STAT notes that ending the program after 2027 may prove challenging.
,
uBlock 
,
and
Ghostery 
)
